Halozyme Therapeutics has been busy. While fighting a patent dispute with Merck & Co. and navigating the impact of the Inflation Reduction Act (IRA), the company has penned an acquisition of fellow drug delivery biotech Elektrofi. Halozyme scoured very broadly for potential acquisitions in the drug delivery field before landing on Elektrofi, Halozyme CEO Helen Torley said during an interview on the sidelines of Fierce Biotech Week in Boston. The San Diego biotech evaluated other areas such as the blood-brain barrier and oral delivery of biologics, looking for companies operating on similar business models, namely, a royalty-generating licensing platform built on a technology with sizable demand from pharma companies.
Read the full article: Halozyme CEO Targets M&A and New Deals as IRA Uncertainty on Pharma Subsides //
Source: https://www.fiercepharma.com/pharma/halozyme-ceo-targets-ma-and-new-deals-ira-uncertainty-pharma-subsides